{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:41:17Z","timestamp":1765276877131,"version":"3.46.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2020-0103_abs_001_w2aab3b7b4b1b6b1aab1c14b2Aa\">\n                    <jats:title>Obejectives<\/jats:title>\n                    <jats:p>Optimal cytoreductive surgery (CRS), followed by adjuvant chemotherapy, is a major predictor of oncological outcome in patients with advanced epithelial ovarian carcinoma (EOC). It is not clear if a delayed start of adjuvant chemotherapy negatively impacts on the oncological outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0103_abs_002_w2aab3b7b4b1b6b1aab1c14b3Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective registry study on 75 patients treated with CRS and hyperthermic intraperitoneal chemotherapy (HIPEC). Adjuvant chemotherapy was started within 42\u00a0days in 41 patients (55%), later on in 34 patients (45%). Multivariate analyses of preoperative factors were done on survival outcome. Outcomes were recurrence-free survival (RFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0103_abs_003_w2aab3b7b4b1b6b1aab1c14b4Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was no difference in RFS after early introduction (median 35\u00a0months) vs. late introduction of chemotherapy (median 32\u00a0months), p\u00a0=\u00a00.17. Median OS in patients with late introduction of chemotherapy was 46\u00a0months and was not yet reached in early introduction group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0103_abs_004_w2aab3b7b4b1b6b1aab1c14b5Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this exploratory study in a small group of women with advanced EOC, starting adjuvant chemotherapy more than 6\u00a0weeks after CRS and HIPEC did not deteriorate significantly RFS or OS. Well-designed clinical studies are still needed to evaluate the interplay of HIPEC and the point of time of postoperative adjuvant chemotherapy in this indication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2020-0103","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T03:03:04Z","timestamp":1597719784000},"source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of delay in time to adjuvant chemotherapy after HIPEC and its impact on oncological outcome in advanced epithelial ovarian cancer"],"prefix":"10.1515","volume":"5","author":[{"given":"S.P.","family":"Somashekhar","sequence":"first","affiliation":[{"name":"Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Ramya","sequence":"additional","affiliation":[{"name":"Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.R.","family":"Ashwin","sequence":"additional","affiliation":[{"name":"Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.Z.","family":"Shabber","sequence":"additional","affiliation":[{"name":"Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.K.","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Amit","sequence":"additional","affiliation":[{"name":"Medical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.C.","family":"Rohit","sequence":"additional","affiliation":[{"name":"Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"2025120909205925112_j_pp-2020-0103_ref_001_w2aab3b7b4b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Bray, F, Ferlay, J, Soerjomataram, I, Siegel, RL, Torre, LA, Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"2025120909205925112_j_pp-2020-0103_ref_002_w2aab3b7b4b1b6b1ab2b2b2Aa","unstructured":"Gunduz, N, Fisher, B, Saffer, EA. Effect of surgical removal on the\u00a0growth and kinetics of residual tumor. Cancer Res 1979;39:3861\u20135."},{"key":"2025120909205925112_j_pp-2020-0103_ref_003_w2aab3b7b4b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Chavez-MacGregor, M, Clarke, CA, Lichtensztajn, DY, Giordano, SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2016;2:322\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3856.","DOI":"10.1001\/jamaoncol.2015.3856"},{"key":"2025120909205925112_j_pp-2020-0103_ref_004_w2aab3b7b4b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Bos, AC, van Erning, FN, van Gestel, YR, Creemers, GJ, Punt, CJ, van Oijen, MG, et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer 2015;51:2553\u201361. https:\/\/doi.org\/10.1016\/j.ejca.2015.08.016.","DOI":"10.1016\/j.ejca.2015.08.016"},{"key":"2025120909205925112_j_pp-2020-0103_ref_005_w2aab3b7b4b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Alexander, M, Blum, R, Burbury, K, Coutsouvelis, J, Dooley, M, Fazil, O, et al. Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice. Intern Med J 2017;47:16\u201334. https:\/\/doi.org\/10.1111\/imj.13190.","DOI":"10.1111\/imj.13190"},{"key":"2025120909205925112_j_pp-2020-0103_ref_006_w2aab3b7b4b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Ozols, RF, Bundy, BN, Greer, BE, Fowler, JM, Clarke-Pearson, D, Burger, RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194\u2013200. https:\/\/doi.org\/10.1200\/JCO.2003.02.153.","DOI":"10.1200\/JCO.2003.02.153"},{"key":"2025120909205925112_j_pp-2020-0103_ref_007_w2aab3b7b4b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Katsumata, N, Yasuda, M, Takahashi, F, Isonishi, S, Jobo, T, Aoki, D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3\u00a0weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(09)61157-0.","DOI":"10.1016\/S0140-6736(09)61157-0"},{"key":"2025120909205925112_j_pp-2020-0103_ref_008_w2aab3b7b4b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Feng, Z, Wen, H, Bi, R, Yang, W, Wu, X. Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecol Oncol 2016;141:466\u201370. https:\/\/doi.org\/10.1016\/j.ygyno.2016.04.016.","DOI":"10.1016\/j.ygyno.2016.04.016"},{"key":"2025120909205925112_j_pp-2020-0103_ref_009_w2aab3b7b4b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Liu, Y, Zhang, T, Wu, Q, Jiao, Y, Gong, T, Ma, X, et al. Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients: a dose-response meta-analysis of cohort studies. Sci Rep 2017;7:9461. https:\/\/doi.org\/10.1038\/s41598-017-10197-1.","DOI":"10.1038\/s41598-017-10197-1"},{"key":"2025120909205925112_j_pp-2020-0103_ref_010_w2aab3b7b4b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Us\u00f3n PL Junior, Bugano, DD, Fran\u00e7a, MS, Antunes, YP, Taranto, P, Kaliks, RA, et al. Does time-to-chemotherapy impact the outcomes of resected ovarian cancer? meta-analysis of randomized and observational data. Int J Gynecol Cancer 2017;27:274\u201380. https:\/\/doi.org\/10.1097\/IGC.0000000000000923.","DOI":"10.1097\/IGC.0000000000000923"},{"key":"2025120909205925112_j_pp-2020-0103_ref_011_w2aab3b7b4b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Elit, L, Oliver, TK, Covens, A, Kwon, J, Fung, MF, Hirte, HW, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with meta analyses. Cancer 2007;109:692\u2013702. https:\/\/doi.org\/10.1002\/cncr.22466.","DOI":"10.1002\/cncr.22466"},{"key":"2025120909205925112_j_pp-2020-0103_ref_012_w2aab3b7b4b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Yan, TD, Cao, CQ, Munkholm-Larsen, S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.World J Gastrointest Oncol 2010;2:109\u201316. https:\/\/doi.org\/10.4251\/wjgo.v2.i2.109.","DOI":"10.4251\/wjgo.v2.i2.109"},{"key":"2025120909205925112_j_pp-2020-0103_ref_013_w2aab3b7b4b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Cavaliere, R, Ciocatto, EC, Giovanella, BC, Heidelberger, C, Johnson, RO, Margottini, M, et al. Selective heat sensitivity of cancer cells Biochemical and clinical studies. Cancer 1967;20:1351\u201381. https:\/\/doi.org\/10.1002\/1097-0142(196709)20:9<1351::aid-cncr2820200902>3.0.co;2-#.","DOI":"10.1002\/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#"},{"key":"2025120909205925112_j_pp-2020-0103_ref_014_w2aab3b7b4b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"van Driel, WJ, Koole, SN, Sikorska, K, Schagen van Leeuwen, JH, Schreuder, HWR, Hermans, RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340.","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909205925112_j_pp-2020-0103_ref_015_w2aab3b7b4b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Somashekhar, SP, Ashwin, KR, Kumar, R, Naidu, N, Yethadka, R, Zaveri, S, et al. Standardization of patient selection and hyperthermic intraperitoneal chemotherapy protocol for peritoneal surface malignancy in indian patients. Indian J Gynecol Oncol 2017;15:55\u201363.","DOI":"10.1007\/s40944-017-0154-9"},{"key":"2025120909205925112_j_pp-2020-0103_ref_016_w2aab3b7b4b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Aletti, GD, Long, HJ, Podratz, KC, Cliby, WA. Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?. Gynecol Oncol 2007;104:212\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2006.07.045.","DOI":"10.1016\/j.ygyno.2006.07.045"},{"key":"2025120909205925112_j_pp-2020-0103_ref_017_w2aab3b7b4b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Hofstetter, G, Concin, N, Braicu, I, Hofstetter, G, Concin, N, Braicu, I, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol 2013;131:15\u201320. https:\/\/doi.org\/10.1016\/j.ygyno.2013.07.086.","DOI":"10.1016\/j.ygyno.2013.07.086"},{"key":"2025120909205925112_j_pp-2020-0103_ref_018_w2aab3b7b4b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Singh, S, Guetzko, M, Resnick, K. Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer. Gynecol Oncol 2016;143:241\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2016.09.004.","DOI":"10.1016\/j.ygyno.2016.09.004"},{"key":"2025120909205925112_j_pp-2020-0103_ref_019_w2aab3b7b4b1b6b1ab2b2c19Aa","unstructured":"Los, G, Mutsaers, PH, van der Vijgh, WJ, Baldew, GS, de Graaf, PW, McVie, JG. Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380\u20134."},{"key":"2025120909205925112_j_pp-2020-0103_ref_020_w2aab3b7b4b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Chang, SJ, Hodeib, M, Chang, J, Bristow, RE. Survival impact of complete cytoreduction to no gross residual disease for primary-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013;130:493\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.040.","DOI":"10.1016\/j.ygyno.2013.05.040"},{"key":"2025120909205925112_j_pp-2020-0103_ref_021_w2aab3b7b4b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Flynn, PM, Paul, J, Cruickshank, DJ, Scottish Gynaecological Cancer Trials Group. Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?. Gynecol Oncol 2002;86:354\u20137. https:\/\/doi.org\/10.1006\/gyno.2002.6750.","DOI":"10.1006\/gyno.2002.6750"},{"key":"2025120909205925112_j_pp-2020-0103_ref_022_w2aab3b7b4b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Gadducci, A, Sartori, E, Landoni, F, Zola, P, Maggino, T, Maggioni, A, et al. Relationship between time interval from primary surgery to the start of taxane-plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol 2005;23:751\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.03.065.","DOI":"10.1200\/JCO.2005.03.065"},{"key":"2025120909205925112_j_pp-2020-0103_ref_023_w2aab3b7b4b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Mahner, S, Eulenburg, C, Staehle, A, Wegscheider, K, Reuss, A, Pujade-Lauraine, E, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur. J.\u00a0Cancer 2013;49:142\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2012.07.023.","DOI":"10.1016\/j.ejca.2012.07.023"},{"key":"2025120909205925112_j_pp-2020-0103_ref_024_w2aab3b7b4b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Tewari, KS, Java, JJ, Eskander, RN, Monk, BJ, Burger, RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology\/Gynecologic Oncology Group study. Ann Oncol 2016;27:114\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdv500.","DOI":"10.1093\/annonc\/mdv500"},{"key":"2025120909205925112_j_pp-2020-0103_ref_025_w2aab3b7b4b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Huo, YR, Richards, A, Liauw, W, Morris, DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2015;41:1578\u201389. https:\/\/doi.org\/10.1016\/j.ejso.2015.08.172.","DOI":"10.1016\/j.ejso.2015.08.172"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/5\/3\/article-20200103.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0103\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0103\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:37:23Z","timestamp":1765276643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0103\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,8,25]]},"published-print":{"date-parts":[[2020,9,4]]}},"alternative-id":["10.1515\/pp-2020-0103"],"URL":"https:\/\/doi.org\/10.1515\/pp-2020-0103","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"type":"electronic","value":"2364-768X"},{"type":"print","value":"2364-7671"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"article-number":"20200103"}}